Recent Updates
Recently added Catalysts

ORMD-0801 Dose # 1

Phase 2

Diabetes Mellitus Type 2 | Small molecule | Metabolic |Oramed Pharmaceuticals Inc.|Last Updated: Apr 15, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01889667Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)PHASE2 COMPLETED 30Jun 1, 2013Nov 1, 2013Apr 15, 2015 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
ORMD-0801 Dose # 1DRUGOral Insulin Formulation
ORMD-0801 Dose # 2DRUGOral Insulin Formulation
PlaceboDRUGOil Capsules
Unlock Study Design Details